




RealRate

PHARMACEUTICAL 2022

PLx Pharma Winddown Corp.
Rank 274 of 466



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of PLx Pharma Winddown Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PLx Pharma Winddown Corp. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 31% points. The greatest weakness of PLx Pharma Winddown Corp. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 49% points.

The company's Economic Capital Ratio, given in the ranking table, is 84%, being 6.2% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	73,476
Cost of Goods Sold	4,805
Intangible Assets	2,061
Liabilities, Current	11,879
Liabilities, Non-Current	136
Other Assets	247
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	12,947
Other Net Income	-5,335
Other Revenues	8,208
Property and Equipment	858
Research and Development	4,182
Selling, General and Administrative Expense	40,011

Output Variable	Value in 1000 USD
Assets	76,642
Liabilities	24,962
Expenses	48,998
Revenues	8,208
Stockholders Equity	51,680
Net Income	-46,125
Comprehensive Net Income	-46,125
Economic Capital Ratio	84%